Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Endocrinology, Diabetes, Type II, Obesity

In brief

This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.

Key facts

Study ID

NCT06851858

Run by

AstraZeneca

People needed

69

Starts

2025-03-12

Expected to finish

2026-05-27

Last updated by the study team

2026-03-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Be 18 to 75 years old at the time of signing the informed consent.
• Diagnosed with type 2 diabetes ≥ 180 days before screening.
• HbA1c value at screening of ≥ 6.0% (42 mmol/mol) and ≤ 10% (86 mmol/mol).
• On a stable maintenance dose of an injectable GLP-1 RA.
• At Screening, have a BMI ≥ 27 kg/m2

You may not qualify if…

• Has received treatment with prescription or non-prescription medication for weight loss within the last 3 months prior to screening (other than a GLP-1 RA).
• Self-reported weight change of > 5 % in the 3 months prior to screening.
• Diabetes mellitus that is not clearly type 2 diabetes.
• Use of insulin therapy for T2DM
• Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
• Significant hepatobiliary disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis)
• Impaired renal function defined as eGFR ≤ 45 mL/minute/1.73m2 at screening

Where it is running

• Research Site — Birmingham, Alabama, United States
• Research Site — Mobile, Alabama, United States
• Research Site — Doral, Florida, United States
• Research Site — Jacksonville, Florida, United States
• Research Site — Miami, Florida, United States
• Research Site — Miami, Florida, United States
• Research Site — Winter Park, Florida, United States
• Research Site — Canton, Georgia, United States
• Research Site — Fayetteville, Georgia, United States
• Research Site — Chicago, Illinois, United States
• Research Site — Oak Brook, Illinois, United States
• Research Site — Newton, Kansas, United States
• Research Site — Lexington, Kentucky, United States
• Research Site — Kansas City, Missouri, United States
• Research Site — Las Vegas, Nevada, United States
• Research Site — Norman, Oklahoma, United States
• Research Site — Knoxville, Tennessee, United States
• Research Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.